Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine

Hypertension

Volumn 51, Issue 2 PART 2, 2008, Pages 528-533

  Tsukuda, Kana ^a   Mogi, Masaki ^a   Li, Jian Mei ^a   Iwanami, Jun ^a   Min, Li Juan ^a   Sakata, Akiko ^a   Fujita, Teppei ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium channel blocker; Cognitive impairment; Diabetes mellitus; Neural differentiation; Oxidative stress

Indexed keywords

INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; NIFEDIPINE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD FLOW; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; MALE; MOUSE; NERVE CELL DIFFERENTIATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR CIRCULATION; COGNITION; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INSULIN; MICE; MICE, MUTANT STRAINS; NIFEDIPINE; RNA, MESSENGER; SUPEROXIDES; UP-REGULATION;

EID: 38549152250     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.101634     Document Type: Conference Paper

References (38)

1. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237-2242.
2. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology. 2004;63:658-663.
3. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.
4. Miles WR, Root HF. Psychologic tests applied in diabetic patients. Arch Intern Med. 1922;30:767-777.
5. Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G. Indices of metabolic dysfunction and oxidative stress. Neurochem Res. 2007;32:717-722.
6. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33:1041-1044.
7. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17:27-45.
8. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Amelioration of cognitive impairment in type-2 diabetic mouse by angiotensin II type-1 receptor blocker, candesartan. Hypertension. 2007;50:1099 -1105.
9. Mooradian AD. The antioxidative potential of cerebral microvessels in experimental diabetes mellitus. Brain Res. 1995;671:164-169.
10. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol. 2002;441:1-14.
11. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943-948.
12. Gao X, Iwai M, Inaba S, Tomono Y, Kanno H, Mogi M, Horiuchi M. Attenuation of monocyte chemoattractant protein-1 expression via inhibition of NF-kappa B activity in inflammatory vascular injury. Am J Hypertens. 2007;20:1170-1175.
13. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240-245.
14. Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc. 2000;48:1285-1291.
15. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther. 2006;319:1081-1087.
16. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111-1115.
17. Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension. 2006;48:141-148.
18. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002;22:21-27.
19. Miller D, Forrester K, Leonard C, Salo P, Bray RC. ACL deficiency impairs the vasoconstrictive efficacy of neuropeptide Y and phenylephrine in articular tissues: a laser speckle perfusion imaging study. J Appl Physiol. 2005;98:329-333.
20. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401:670-677.
21. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res. 1996;75:1-11.
22. Elangovan V, Kohen R, Shohami E. Neurological recovery from closed head injury is impaired in diabetic rats. J Neurotrauma. 2000;17:1013-1027.
23. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999;56:1135-1140.
24. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187-1192.
25. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes. 2000;49:1525-1533.
26. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D Jr. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides. 1990;11:467-472.
27. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007;56:1817-1824.
28. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004;18:902-904.
29. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, Zanetti O, Guralnik JM, Ferrucci L. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol. 2005;62:1067-1072.
30. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, Baudry M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A. 2003;100:8526-8531.
31. Kabos P, Kabosova A, Neuman T. Neuronal injury affects expression of helix-loop-helix transcription factors. Neuroreport. 2002;13:2385-2388.
32. Mastaitis JW, Wurmbach E, Cheng H, Sealfon SC, Mobbs CV. Acute induction of gene expression in brain and liver by insulin-induced hypoglycemia. Diabetes. 2005;54:952-958.
33. Tanaka K, Pracyk JB, Takeda K, Yu ZX, Ferrans VJ, Deshpande SS, Ozaki M, Hwang PM, Lowenstein CJ, Irani K, Finkel T. Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism. J Biol Chem. 1998;273:25922-25928.
34. Schwartz BL, Fay-McCarthy M, Kendrick K, Rosse RB, Deutsch SI. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. Clin Neuropharmacol. 1997;20:364-370.
35. Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci. 1994;747:1-11.
36. Kappelle AC, Biessels G, Bravenboer B, van Buren T, Traber J, de Wildt DJ, Gispen WH. Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat. Br J Pharmacol. 1994;111:887-893.
37. Farkas E, De Jong GI, Apro E, Keuker JI, Luiten PG. Calcium antagonists decrease capillary wall damage in aging hypertensive rat brain. Neurobiol Aging. 2001;22:299-309.
38. Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG. Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc Natl Acad Sci U S A. 1999;96:6468-6472.